» Articles » PMID: 32295254

Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors

Overview
Journal Cells
Publisher MDPI
Date 2020 Apr 17
PMID 32295254
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma, Ewing sarcoma and chondrosarcoma are rare diseases but the most common primary tumors of bone. The genes directly involved in the sarcomagenesis, tumor progression and treatment responsiveness are not completely defined for these tumors, and the powerful discovery of genetic analysis is highly warranted in the view of improving the therapy and cure of patients. The review summarizes recent advances concerning the molecular and genetic background of these three neoplasms and, of their most common variants, highlights the putative therapeutic targets and the clinical trials that are presently active, and notes the fundamental issues that remain unanswered. In the era of personalized medicine, the rarity of sarcomas may not be the major obstacle, provided that each patient is studied extensively according to a road map that combines emerging genomic and functional approaches toward the selection of novel therapeutic strategies.

Citing Articles

A genomic strategy for precision medicine in rare diseases: integrating customized algorithms into clinical practice.

Mendez-Vidal C, Bravo-Gil N, Perez-Florido J, Marcos-Luque I, Fernandez R, Fernandez-Rueda J J Transl Med. 2025; 23(1):86.

PMID: 39833864 PMC: 11748347. DOI: 10.1186/s12967-025-06069-2.


Mitochondrial inhibitors: a new horizon in breast cancer therapy.

Yan Y, Li S, Su L, Tang X, Chen X, Gu X Front Pharmacol. 2024; 15:1421905.

PMID: 39027328 PMC: 11254633. DOI: 10.3389/fphar.2024.1421905.


Editorial: New therapies in the treatment of sarcomas.

Gartland A, Pasello M, Lezot F, Lamoureux F Front Endocrinol (Lausanne). 2023; 14:1137736.

PMID: 36742406 PMC: 9890148. DOI: 10.3389/fendo.2023.1137736.


Polymorphic variants of and have an impact on predisposition and/or progression of Ewing sarcoma.

Martinelli M, Mancarella C, Scapoli L, Palmieri A, De Sanctis P, Ferrari C Front Oncol. 2022; 12:968884.

PMID: 36338681 PMC: 9634078. DOI: 10.3389/fonc.2022.968884.


Molecular Markers of Pediatric Solid Tumors-Diagnosis, Optimizing Treatments, and Determining Susceptibility: Current State and Future Directions.

Trubicka J, Grajkowska W, Dembowska-Baginska B Cells. 2022; 11(7).

PMID: 35406801 PMC: 8997439. DOI: 10.3390/cells11071238.


References
1.
Zhang Y, van Oosterwijk J, Sicinska E, Moss S, Remillard S, van Wezel T . Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin Cancer Res. 2013; 19(14):3796-807. DOI: 10.1158/1078-0432.CCR-12-3647. View

2.
Sandberg A, Bridge J . Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet. 2003; 145(1):1-30. View

3.
Rosas S, Koch W, da Costa Carvalho M, Wu L, Califano J, Westra W . Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001; 61(3):939-42. View

4.
Gelderblom H, Hogendoorn P, Dijkstra S, van Rijswijk C, Krol A, Taminiau A . The clinical approach towards chondrosarcoma. Oncologist. 2008; 13(3):320-9. DOI: 10.1634/theoncologist.2007-0237. View

5.
Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X . Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer. 2006; 106(7):1602-9. DOI: 10.1002/cncr.21762. View